vs
Side-by-side financial comparison of Electromed, Inc. (ELMD) and EVERSPIN TECHNOLOGIES INC. (MRAM). Click either name above to swap in a different company.
Electromed, Inc. is the larger business by last-quarter revenue ($18.9M vs $14.9M, roughly 1.3× EVERSPIN TECHNOLOGIES INC.). Electromed, Inc. runs the higher net margin — 14.6% vs -2.0%, a 16.6% gap on every dollar of revenue. On growth, Electromed, Inc. posted the faster year-over-year revenue change (16.3% vs 13.2%). Over the past eight quarters, EVERSPIN TECHNOLOGIES INC.'s revenue compounded faster (18.2% CAGR vs 16.7%).
Electromed, Inc. is a specialized medical device firm developing, manufacturing, and distributing advanced respiratory care products. Its core offerings are high-frequency chest wall oscillation systems that clear airway secretions for patients with cystic fibrosis, COPD and other respiratory conditions, serving U.S. home care and clinical customers.
Everspin Technologies, Inc. is a publicly traded semiconductor company headquartered in Chandler, Arizona, United States. It develops and manufactures discrete magnetoresistive RAM or magnetoresistive random-access memory (MRAM) products, including Toggle MRAM and Spin-Transfer Torque MRAM (STT-MRAM) product families. It also licenses its technology for use in embedded MRAM (eMRAM) applications, magnetic sensor applications as well as performs backend foundry services for eMRAM.
ELMD vs MRAM — Head-to-Head
Income Statement — Q2 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $18.9M | $14.9M |
| Net Profit | $2.8M | $-296.0K |
| Gross Margin | 78.4% | 52.7% |
| Operating Margin | 19.2% | 29.0% |
| Net Margin | 14.6% | -2.0% |
| Revenue YoY | 16.3% | 13.2% |
| Net Profit YoY | 40.3% | — |
| EPS (diluted) | $0.32 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $14.9M | ||
| Q4 25 | $18.9M | $14.8M | ||
| Q3 25 | $16.9M | $14.1M | ||
| Q2 25 | $17.4M | $13.2M | ||
| Q1 25 | $15.7M | $13.1M | ||
| Q4 24 | $16.3M | $13.2M | ||
| Q3 24 | $14.7M | $12.1M | ||
| Q2 24 | $14.8M | $10.6M |
| Q1 26 | — | $-296.0K | ||
| Q4 25 | $2.8M | $1.2M | ||
| Q3 25 | $2.1M | $54.0K | ||
| Q2 25 | $2.2M | $-670.0K | ||
| Q1 25 | $1.9M | $-1.2M | ||
| Q4 24 | $2.0M | $1.2M | ||
| Q3 24 | $1.5M | $2.3M | ||
| Q2 24 | $1.8M | $-2.5M |
| Q1 26 | — | 52.7% | ||
| Q4 25 | 78.4% | 50.8% | ||
| Q3 25 | 78.1% | 51.3% | ||
| Q2 25 | 78.3% | 51.3% | ||
| Q1 25 | 78.0% | 51.4% | ||
| Q4 24 | 77.7% | 51.3% | ||
| Q3 24 | 78.3% | 49.2% | ||
| Q2 24 | 76.2% | 49.0% |
| Q1 26 | — | 29.0% | ||
| Q4 25 | 19.2% | -7.2% | ||
| Q3 25 | 15.8% | -11.0% | ||
| Q2 25 | 17.5% | -14.9% | ||
| Q1 25 | 13.6% | -14.7% | ||
| Q4 24 | 15.6% | -11.8% | ||
| Q3 24 | 13.2% | -17.5% | ||
| Q2 24 | 15.7% | -26.5% |
| Q1 26 | — | -2.0% | ||
| Q4 25 | 14.6% | 8.1% | ||
| Q3 25 | 12.6% | 0.4% | ||
| Q2 25 | 12.7% | -5.1% | ||
| Q1 25 | 12.1% | -8.9% | ||
| Q4 24 | 12.1% | 9.2% | ||
| Q3 24 | 10.0% | 18.8% | ||
| Q2 24 | 12.3% | -23.5% |
| Q1 26 | — | $-0.01 | ||
| Q4 25 | $0.32 | $0.05 | ||
| Q3 25 | $0.25 | $0.00 | ||
| Q2 25 | $0.26 | $-0.03 | ||
| Q1 25 | $0.21 | $-0.05 | ||
| Q4 24 | $0.22 | $0.07 | ||
| Q3 24 | $0.16 | $0.10 | ||
| Q2 24 | $0.20 | $-0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $13.8M | $40.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $45.4M | $70.2M |
| Total Assets | $54.9M | $83.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $40.5M | ||
| Q4 25 | $13.8M | $44.5M | ||
| Q3 25 | $14.1M | $45.3M | ||
| Q2 25 | $15.3M | $45.0M | ||
| Q1 25 | $15.2M | $42.2M | ||
| Q4 24 | $16.2M | $42.1M | ||
| Q3 24 | $13.9M | $39.6M | ||
| Q2 24 | $16.1M | $36.8M |
| Q1 26 | — | $70.2M | ||
| Q4 25 | $45.4M | $68.9M | ||
| Q3 25 | $44.7M | $65.8M | ||
| Q2 25 | $43.2M | $64.1M | ||
| Q1 25 | $43.9M | $63.0M | ||
| Q4 24 | $43.6M | $62.6M | ||
| Q3 24 | $41.5M | $59.3M | ||
| Q2 24 | $44.5M | $55.4M |
| Q1 26 | — | $83.2M | ||
| Q4 25 | $54.9M | $84.6M | ||
| Q3 25 | $53.6M | $80.3M | ||
| Q2 25 | $53.8M | $78.9M | ||
| Q1 25 | $52.5M | $80.2M | ||
| Q4 24 | $52.3M | $77.8M | ||
| Q3 24 | $48.9M | $72.6M | ||
| Q2 24 | $52.2M | $64.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.0M | $570.0K |
| Free Cash FlowOCF − Capex | $2.4M | — |
| FCF MarginFCF / Revenue | 12.7% | — |
| Capex IntensityCapex / Revenue | 3.4% | — |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $7.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $570.0K | ||
| Q4 25 | $3.0M | $2.6M | ||
| Q3 25 | $169.0K | $881.0K | ||
| Q2 25 | $3.9M | $5.0M | ||
| Q1 25 | $2.1M | $1.4M | ||
| Q4 24 | $3.2M | $3.8M | ||
| Q3 24 | $2.3M | $2.8M | ||
| Q2 24 | $4.5M | $1.7M |
| Q1 26 | — | — | ||
| Q4 25 | $2.4M | $-975.0K | ||
| Q3 25 | $-83.0K | $543.0K | ||
| Q2 25 | $3.7M | $3.0M | ||
| Q1 25 | $1.9M | $527.0K | ||
| Q4 24 | $2.9M | $2.1M | ||
| Q3 24 | $2.3M | $2.8M | ||
| Q2 24 | $4.5M | $1.7M |
| Q1 26 | — | — | ||
| Q4 25 | 12.7% | -6.6% | ||
| Q3 25 | -0.5% | 3.9% | ||
| Q2 25 | 21.4% | 22.9% | ||
| Q1 25 | 12.2% | 4.0% | ||
| Q4 24 | 18.0% | 15.8% | ||
| Q3 24 | 15.5% | 22.9% | ||
| Q2 24 | 30.1% | 15.9% |
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | 24.3% | ||
| Q3 25 | 1.5% | 2.4% | ||
| Q2 25 | 0.8% | 15.1% | ||
| Q1 25 | 1.0% | 6.9% | ||
| Q4 24 | 1.4% | 13.2% | ||
| Q3 24 | 0.3% | 0.5% | ||
| Q2 24 | 0.1% | 0.3% |
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 2.19× | ||
| Q3 25 | 0.08× | 16.31× | ||
| Q2 25 | 1.75× | — | ||
| Q1 25 | 1.10× | — | ||
| Q4 24 | 1.60× | 3.16× | ||
| Q3 24 | 1.57× | 1.25× | ||
| Q2 24 | 2.46× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELMD
| Homecare | $17.3M | 91% |
| Other | $1.6M | 9% |
MRAM
| Product sales | $14.1M | 95% |
| Licensing, royalty, patent, engineering services and other revenue | $772.0K | 5% |
